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Background: Subarachnoid haemorrhage (SAH) is a devastating disease, in the majority of cases caused by a
rupture of an arterial intracranial aneurysm. The effect of systemic low-grade inflammation on incidence of SAH is
not known. The purpose of this study was to evaluate the relationship between leukocyte count, a marker of
systemic inflammation, and incidence of SAH in a large cohort study.
Methods: Leukocyte count and other cardiovascular risk factors were measured in 19,794 individuals (17,083 men
and 2,711 women, mean age 44 years) participating in a health screening program between 1974 and 1981.
Incidence of SAH in relation to baseline leukocyte concentration was studied during a mean follow-up of 27 years
in participants free from previous stroke.
Results: Ninety-five participants had a SAH, corresponding to an incidence of 22 per 100,000 in women and 17 per
100,000 in men. The hazard ratio for SAH per one standard deviation (2.01 × 109 cells/L) increase of leukocyte
concentration was 1.26 (95% CI 1.05-1.53, p = 0.014) after adjustment for several potential confounding factors
including smoking. In sensitivity analysis, there was a significant association in smokers but not in non-smokers.
Conclusions: High leukocyte count at baseline was associated with increased incidence of SAH, although this
relationship might be restricted to smokers. The results support the view that low-grade systemic inflammation
could be involved in the pathogenesis of SAH, or constitute an early risk marker for the disease.
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Subarachnoid haemorrhage (SAH) constitutes approxi-
mately 5% all strokes [1]. SAH is associated with a high
mortality and morbidity [2] and is a disease of high clin-
ical importance. In the majority of cases (approximately
85%) SAH is caused by a rupture of an arterial intracra-
nial aneurysm [3,4]. Important risk factors for SAH are
female sex, family history, hypertension, smoking and
excessive alcohol consumption [4,5].
The pathogenic mechanisms leading to aneurysm for-
mation and rupture are, however, not fully understood.
Infiltration of inflammatory cells and increased expres-
sion of inflammatory mediators have been observed in
the aneurysm wall in histological studies, and are more
pronounced in ruptured than unruptured aneurysms.* Correspondence: martin.soderholm@med.lu.se
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distribution, and reproduction in any mediumThese inflammatory changes might occur prior to
aneurysm formation and rupture, or be a reaction to
the degeneration of the aneurysm wall [6].
Systemic low-grade inflammation, measured as levels
of leukocytes, high sensitive C-reactive protein (hsCRP)
or fibrinogen, is involved in development of atheroscler-
osis and associated with incidence of ischemic stroke
and coronary heart disease in prospective studies [7-12].
There is also an immuno-inflammatory activation after
acute ischemic stroke onset, contributing to the develop-
ment of acute brain ischemia [13,14]. Plasma levels of
several immuno-inflammatory markers are associated
with a diagnosis of ischemic stroke, [14] although the
plasma markers could differ between subtypes of ische-
mic stroke [13].
It is not known whether systemic low-grade inflamma-
tion is associated with the incidence of SAH, and only
two prospective studies have addressed this question. In
one study incidence of SAH was evaluated in relation totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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gen [10]. No significant associations were found in any
of the studies, possibly due to the low numbers of SAH
events. Leukocyte concentration in relation to incidence
of SAH has, to our best knowledge, not earlier been
studied. In this study we investigated the association be-
tween leukocyte count and incident SAH in a large pro-
spective cohort study from an urban population.
Methods
Study population
Between 1974 and 1992, a screening program with the
aim to identify individuals at high risk for cardiovascular
disease, the Malmö preventive project, was conducted in
Malmö, Sweden [16]. Complete birth cohorts, born
between 1921 and 1949, were invited to a health exam-
ination including a physical examination, a panel of la-
boratory tests and a self-administered questionnaire. A
total of 22,444 men were examined from 1974 to 1984
and 10,902 women were examined between 1977 and
1992. The Health Service Authority of Malmö approved
the screening program, and all participants gave in-
formed consent. Linkage with the national hospital dis-
charge register and the causes of death register was
approved by the ethics committee at Lund University.
In the Malmö preventive project, leukocyte count was
measured in participants invited between 1974 and
1981. During this period, men born in 1921, 1926–1940,
1942, 1944, 1946 and 1949 were invited, and women
born in 1926, 1931, 1938, and 1949. A total of 19,930
subjects, 2,732 women and 17,198 men, participated.
Participation rate was 71% both for men and women.
Subjects with a history of stroke (n = 10), and those
with missing information about systolic blood pressure
(n = 14), total cholesterol (n = 28) and diabetes (n = 81)
were excluded. We also excluded seven individuals with
leukocyte counts >20.0 × 109 cells/L as extreme outliers
from the population distribution, since they may have
had a subclinical hematologic disease or laboratory error
at baseline [12]. A total of 19,794 participants (2,711
women and 17,083 men) with a mean age ± SD of 44 ±
6 years remained for the analysis. Mean age in women
was 42 ± 9 years (range 28–54) and in men 44 ± 5 years
(range 27–61).
Baseline examinations
Blood pressure (mm Hg) was measured twice in the
right arm after 10 minutes of rest. The average of two
measurements was used. A sphygmomanometer and a
rubber cuff of appropriate size were used. Height (cm)
and weight (kg) were measured under standardized con-
ditions and body mass index was calculated as weight/
height2 (kg/m2). Current smoking habits, alcohol con-
sumption and use of antihypertensive medication wereevaluated in a questionnaire. Subjects were categorized
in terms of smoking as never smokers, former smokers
(i.e. non-smokers who previously had been smoking
daily for at least 6 months) and current smokers (i.e. daily
smoking).
Alcohol abuse was assessed by means of the modified
shortened version of the Michigan Alcoholism Screening
Test [17]. Subjects with more than two (of nine) af-
firmative answers were considered to have high alcohol
consumption. Information about previous myocardial
infarction (MI) before screening was based on the ques-
tionnaire and data from the Swedish hospital discharge
register. Subjects who confirmed a doctor’s diagnosis of
angina pectoris or who used nitrates were considered to
have angina pectoris (AP). In the present study preva-
lent MI and AP was combined into one variable; history
of MI or AP. Physical inactivity in spare time was
assessed using the question: ‘Are you mostly engaged in
sedentary activities in spare time, for example, watching
TV, reading, going to the movies?’.
Blood samples were taken after an overnight fast.
Leukocyte count was determined with automatic coun-
ters in accordance with standard methods at the hos-
pital laboratory. Serum cholesterol and blood glucose
were analysed with standard methods. Diabetes was de-
fined as fasting whole blood glucose > 6.1 mmol/L or
self-reported treatment for diabetes. Forced expiratory
volume in one second (FEV1) was measured in a sub-
sample (n = 18,607, 94%) of the present cohort, using
spirometry. The methods for the lung function assess-
ment and standardization of FEV1 to percentages of the
individuals predicted value have been described else-
where [18].
Retrieval of cases
All subjects were followed from the baseline examin-
ation until first SAH, death, emigration from Sweden or
December 31, 2008, whichever came first. SAH cases
were identified with the Malmö stroke register, the
Swedish hospital discharge register or the causes of
death register (ICD 8 and 9 code 430, and ICD 10 code
I60), as previously described [18]. These registers pro-
vide complete coverage of hospital discharges and deaths
in Sweden. All diagnoses are made by a physician at hos-
pital discharge or death of the patient, and contra-signed
by board-certified specialists [19].
Statistical analysis
Leukocyte count was categorized into sex-specific quar-
tiles with equal proportions of women in each quartile,
in order to adjust for the relationship between sex and
SAH. One-way analysis of variance (for continuous vari-
ables) and logistic regression (for categorical variables)
were used for cross-sectional analyses of the risk factor
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Cox proportional hazards regression was used to calculate
risk factor-adjusted hazard ratios (HR) and 95% confi-
dence intervals (CI). Leukocyte concentration was evalu-
ated as a continuous variable (per 1-SD increase) and in
sex-specific quartiles. Unadjusted results and results from
a multivariable model adjusted for the categorical vari-
ables sex, smoking status, antihypertensive medication,
high alcohol consumption, diabetes and physical inactivity,
and the continuous age, systolic blood pressure, body
mass index, cholesterol, are presented. To explore whether
FEV1 or a history of MI/AP, explained the relationship be-
tween leukocytes and SAH, these covariates were entered
separately to the multivariable model. Covariates were se-
lected because they have shown associations with SAH [5]
and systemic inflammation [20], respectively, and thus are
potential confounders of the association between SAH and
leukocytes. The fit of the proportional hazards model was
checked visually by plotting the incidence rates over time,
and by plotting Schoenfeld residuals as a function of time
and statistically testing for a non-zero slope. Possible inter-
actions between leukocyte count and each covariate, re-
spectively, were checked by interaction terms added to the
full model. The Cox regression analyses were also per-
formed separately in current, former and never smokers,
and in women and men. Harrell’s C statistics was used to
estimate the ability of the risk factor adjusted Cox model
to predict SAH.Table 1 Baseline characteristics by sex-specific quartiles of le
Q1 Q2
n 5110 4864
Leukocytes, 109 cells/L 3.93 ± 0.5 5.17 ± 0.3
Leukocytes, 109 cells/L, range 2.0-4.6 4.6-5.7
Women, % 13.4 13.1
Age, years 43.6 ± 6.1 43.8 ± 6.0
Systolic blood pressure, mmHg 126 ± 14 127 ± 15
Smoking status, %
Never smokers 50.2 38.2
Former smokers 24.6 22.4
Current smokers 25.2 39.4
High alcohol consumption, % 12.1 13.3
Antihypertensive medication, % 3.4 3.6
Body mass index, kg/m2 24.2 ± 3.1 24.6 ± 3.4
Cholesterol, mmol/L 5.51 ± 1.0 5.58 ± 1.0
Diabetes, % 2.1 2.2
Physical inactivity, % 50.9 54.8
History of MI or AP, % 1.8 1.5
FEV1, % of predicted 97.5 ± 17.6 95.6 ± 17.4
Values are mean ± SD or percentages.
Q, quartile; MI, myocardial infarction; AP, angina pectoris; FEV1, forced expiratory voResults
Baseline characteristics
Baseline characteristics by quartiles of leukocytes are de-
scribed in Table 1. Leukocyte count was significantly as-
sociated with systolic blood pressure, current smoking,
high alcohol intake, body mass index, total cholesterol,
diabetes and physical inactivity.
Incidence of SAH
During the mean follow-up of 26.8 ± 6.9 years (530,562
person years), ninety-five subjects (78 men and 17
women) had a SAH, corresponding to a crude incidence
of 17.9 per 100,000 person years (17.2 in men and 22.1 in
women). Mean age at SAH was 58.1 ± 11 years and mean
time from screening to SAH was 15.1 ± 8.4 years.
Higher leukocyte concentration was significantly associ-
ated with higher incidence of SAH. Per 1 SD (2.01 × 109
cells/L) increase of leukocytes, the crude HR (95% CI) for
SAH was 1.30 (1.09-1.54), p = 0.003, and the HR after ad-
justment in the multivariable model 1.26 (1.05-1.53), p =
0.014 (Table 2). After additionally adjusting for FEV1 (in %
of the predicted values) HR was 1.25 (1.04-1.52), p = 0.020,
per SD increase of leukocytes. Further adjusting for history
of MI/AP did not substantially change the result.
To explore if the relationship between leukocytes and
SAH changed with time, the follow-up was divided at the
median follow-up time for those with SAH (14.6 years)
and separate models was fitted for the two intervals. Theukocyte count
Q3 Q4 p trend All
4794 5026 19,794
6.33 ± 0.4 8.74 ± 1.6 6.04 ± 2.01
5.6-7.0 7.1-19.2 2.0-19.2
15.1 13.2 13.7
43.7 ± 6.1 43.9 ± 5.9 0.055 43.7 ± 6.0
127 ± 16 127 ± 16 0.028 126 ± 15
27.5 13.2 < 0.001 32.3
16.4 8.4 < 0.001 18.0
56.1 78.4 < 0.001 49.7
14.5 17.6 < 0.001 14.4
4.1 4.0 0.057 3.8
24.7 ± 3.6 24.4 ± 3.5 0.002 24.5 ± 3.4
5.62 ± 1.0 5.76 ± 1.1 < 0.001 5.61 ± 1.1
2.6 2.9 0.005 2.5
56.7 58.9 < 0.001 55.3
2.0 2.1 0.093 1.8
93.4 ± 17.4 91.1 ± 17.5 < 0.001 94.4 ± 17.7
lume in 1 s (n = 18,607).
Table 2 Hazard ratios for subarachnoid haemorrhage per 1 standard deviation increase of leukocytes and in relation
to sex-specific quartiles of leukocytes, for all participants and stratified by sex and smoking status
Q1 Q2 Q3 Q4 Per 1-SD increase p value
All
n 5110 4864 4794 5026 19794
SAH, n 15 23 27 30 95
HR (95% CI) 1 1.65 (0.86-3.16) 2.00 (1.06-3.76) 2.22 (1.19-4.12) 1.30 (1.09-1.54) 0.003
HR* 1 1.63 (0.85-3.14) 1.92 (1.00-3.66) 2.05 (1.06-3.96) 1.26 (1.05-1.53) 0.014
Men
n 4423 4227 4072 4361 17083
SAH, n 11 20 22 25 78
HR 1 1.95 (0.93-4.07) 2.27 (1.10-4.69) 2.53 (1.25-5.15) 1.28 (1.05-1.55) 0.013
HR* 1 1.99 (0.95-4.18) 2.35 (1.12-4.94) 2.63 (1.23-5.62) 1.28 (1.04-1.59) 0.021
Women
n 687 637 722 665 2711
SAH, n 4 3 5 5 17
HR 1 0.81 (0.18-3.64) 1.21 (0.32-4.51) 1.32 (0.36-4.93) 1.37 (0.95-1.97) 0.095
Never smokers
n 2563 1858 1317 665 6403
SAH, n 5 10 8 2 25
HR 1 2.80 (0.96-8.18) 3.18 (1.04-9.72) 1.60 (0.31-8.24) 1.31 (0.82-2.11) 0.257
Former smokers
n 1249 1085 783 420 3555
SAH, n 8 5 3 2 18
HR 1 0.74 (0.24-2.26) 0.62 (0.16-2.34) 0.81 (0.17-3.80) 0.93 (0.49-1.78) 0.824
Current smokers
n 1288 1908 2635 3913 9836
SAH, n 2 8 16 26 52
HR 1 2.72 (0.58-12.8) 3.88 (0.89-16.9) 4.47 (1.06-18.8) 1.33 (1.07-1.65) 0.010
HR* 1 2.73 (0.58-12.8) 3.91 (0.90-17.0) 4.51 (1.07-19.0) 1.32 (1.06-1.63) 0.011
*Adjusted for age, sex, systolic blood pressure, antihypertensive medication, smoking status, high alcohol consumption, body mass index, diabetes, total
cholesterol and physical inactivity. This model was not applied in all subgroups, due to limited number of events.
1 SD; 2.01 × 109 cells/L. Q; quartile. SAH; subarachnoid haemorrhage. HR; hazard ratio.
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in the first and second time period (p for interaction with
time 0.9).
There were no statistically significant interactions be-
tween leukocytes and other variables in the analysis. In
subgroup-analysis, the association between SAH inci-
dence and leukocyte concentration (per 1 SD) remained
significant in men (p = 0.021) and in smokers (p = 0.011)
after full adjustment. The full multivariate model could
not be applied in all subgroups due to the limited num-
ber of events (Table 2).
The association between leukocyte count and incident
SAH was significant in a dose–response manner when
leukocyte concentration was analysed in sex-specific
quartiles (unadjusted p for trend = 0.010), Table 2 and
Figure 1.Adding leukocyte concentration (continuous/per 1
SD) to the other variables in the full multivariable model
increased the SAH predictive ability of the model (c sta-
tistics 0.6248 vs. 0.6439).
Discussion
In the present prospective cohort study, systemic inflam-
mation measured by the leukocyte count was associated
with incidence of SAH in a representative sample of
healthy middle-aged subjects from the general population.
The association persisted during a long follow-up time,
also after adjustment for established SAH risk factors [5]
including smoking. However, the association between
SAH and leukocytes might be limited to smokers.
To our best knowledge, no study has previously evaluated
leukocyte count and incidence of SAH. A relationship
Figure 1 Incidence of subarachnoid haemorrhage by sex-specific
quartiles of leukocytes.
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has been shown in a meta-analysis but no distinction of
SAH and ICH was made [9]. Two prospective studies have
examined the effect of markers of systemic inflammation,
hsCRP [15] and fibrinogen, [10] in relation to SAH inci-
dence. No significant associations were found in any of
the studies. However, because the studies included only 29
and 33 SAH cases, respectively, they could be underpow-
ered. Some published studies could provide indirect sup-
port to the hypothesis of systemic inflammation in
development of SAH. For example, polymorphisms of the
interleukin 6 gene, a stimulator of inflammatory plasma
proteins, have shown association with intracranial
aneurysm prevalence [21] and an increased risk of
SAH has been found in patients with systemic lupus
erythematosus [22]. It needs to be further studied
whether other systemic markers of inflammation (e.g.
CRP or interleukin 6) are associated with SAH and if
their ability to predict SAH is higher in comparison
with leukocytes.
Smoking is one of the most important risk factors for
SAH [5]. The relationship between leukocytes and SAH
was significant after adjustment for smoking, but in sub-
groups analysis, a significant association was only ob-
served in smokers but not in non-smokers. However,
there was no significant interaction between leukocytes
and smoking. The absence of an association in non-
smokers might be due to low statistical power leading to
the association being undetected. The observation of a
similar point estimate for the HR in never smokers and
smokers might support this view, although this is not
true for former smokers. Alternatively, the relationship
between leukocytes and SAH could be an effect ofsmoking, i.e. inflammation could be a mediator of the
increased SAH risk in smokers. If so, leukocytes could
be a marker of increased susceptibility to the deleterious
effects of smoking. As previously suggested, this could
work through neutrophils secreting proteolytic enzymes
in response to cigarette smoke, promoting degradation
of elastin and collagen and thus formation of aneurysms
[23]. Although we do not have data on neutrophil level,
this study then adds to the knowledge by showing that
levels of leukocytes, not just their enzymes, are elevated
in smokers developing SAH many years before the
event. Larger studies will be needed to determine if
leukocyte count is a risk factor for SAH also in non-
smokers.
It is not known if SAH can be caused by atheroscler-
osis, but atherosclerosis can be present in cerebral aneu-
rysms [24]. Because atherosclerotic disease is associated
with raised leukocytes, this might contribute to the rela-
tionship between leukocytes and SAH. However, in the
present study there were no significant interactions be-
tween leukocytes and other cardiovascular risk factors
on incidence of SAH, and adjusting for a history of MI
or AP did not change the results. It should be acknowl-
edged, though, that interaction analyses require relatively
high number of events, and the statistical power might
be too low for these analyses.
The main strengths of this study include the prospect-
ive population-based design, a high participation rate of
middle-aged, healthy subjects from an urban population,
a long follow-up time, and a relatively high number of
SAH cases. Further, using hospital-based registers for
case retrieval is appropriate because all non-fatal SAH
patients should be admitted to hospital. SAH cases dying
unexpectedly outside of hospital were identified with the
causes of death registry, and for these cases the diagnosis
was based on autopsy in 10 cases out of 11. In the local
stroke register all diagnoses are verified by review of the
patient records. SAH diagnoses identified with the na-
tional hospital discharge registry were reviewed with re-
spect to which clinic the patient was treated in and what
surgical procedure that was undertaken to treat SAH.
Some limitations need to be considered. Despite the
relatively high number of SAH events in the present co-
hort, events are too few to perform analysis of all sub-
groups. Second, elevated leukocyte count is a non-specific
sign of inflammation and there could be many underlying
causes. Some individuals might have had acute infections
causing elevation of leukocytes at baseline. However, mis-
classification of some individuals with high leukocytes due
to acute infection would weaken the association between
leukocytes and SAH. Even though the cohort consists of
individuals from the general population, it is also possible
that a few participants had a systemic inflammatory dis-
ease, e.g. SLE or rheumatoid arthritis. Even though these
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morbid conditions could still contribute to the association
between leukocytes and SAH.
There are also several drugs, e.g. non-steroid anti-
inflammatory drugs, statins, corticosteroids and blood
pressure drugs, which could theoretically influence the
level of leukocytes and perhaps also the risk of SAH.
Blood pressure medication was slightly more common
in those with higher leukocytes, and adjustment for this
did not change the results substantially. Statins were not
on the market when the baseline examinations were per-
formed, and aspirin was not used for prevention of car-
diovascular disease at that time. We had no information
about the other mentioned drugs. There is no obvious
reason to believe that medication of any kind could ex-
plain the present results. Further studies are needed to
explore whether anti-inflammatory drugs also could re-
duce the risk of SAH.
Third, we included all non-traumatic SAHs. Approxi-
mately 85-90% of non-traumatic SAHs are aneurysmal,
so the results do not represent only aneurysmal SAH.
Further, leukocytes were only measured at one time-
point, and we do not know to what extent leukocyte
concentrations changed during follow-up. It has been
shown that leukocyte concentrations are rather stable
over time [25] and substantially influenced by genetic
factors [26]. The present results also show that the asso-
ciation between leukocytes and SAH was essentially un-
changed with time, which is unlikely if there are great
intra-individual variations. Misclassification of the ex-
posure due to individual biological variation over time
will be non-differential and dilute the association be-
tween leukocytes and SAH [27]. This is also supported
by previous studies taking into account the variation
over time when assessing the relationship between leu-
kocytes and cardiovascular disease [28].
Conclusions
In conclusion, high leukocyte count at baseline was asso-
ciated with increased incidence of SAH, although this
might be restricted to smokers. The results support the
view that inflammation might precede the development
of SAH and mediate the effect of smoking on SAH.
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